In stock COA-30%
NOVALYTE
LABS
LABS
NOVALYTELABS
Survodutide5mg · RESEARCH USE ONLY
Survodutide5mg · RESEARCH USE ONLY
In stock COA DOCUMENT SLOT-30%
Metabolic ResearchSurvodutide
Dual GLP-1/glucagon receptor agonist by Boehringer Ingelheim — studied for metabolic and hepatic lipid research.
Research catalogueLaboratory-use positioning
Batch documentationBatch certificate supplied with order
Order trackingFrom payment to dispatch
Product information
CompoundSurvodutide
Presentation5mg injection pen
CategoryMetabolic Research
AvailabilityIn stock
Batch COACertificate supplied with order
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use.
Overview
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim, currently in Phase 3 clinical trials for obesity and metabolic liver disease. Unlike dual GLP-1/GIP agonists, survodutide uniquely combines GLP-1 receptor agonism with glucagon receptor activation — leveraging glucagon's thermogenic and lipolytic properties. Phase 2 results demonstrated approximately 16.6% average weight loss at the highest dose after 76 weeks, with notable improvements in hepatic steatosis markers.
Mechanism of Action
Survodutide engages two complementary receptor pathways. GLP-1 receptor activation promotes satiety through hypothalamic signalling, delays gastric emptying, and enhances glucose-dependent insulin secretion. Glucagon receptor agonism — the distinguishing feature — increases hepatic energy expenditure through enhanced lipid oxidation, stimulates thermogenesis, and promotes hepatic fat mobilisation. This unique combination addresses both caloric intake (via GLP-1) and energy expenditure (via glucagon), while the GLP-1 component counterbalances glucagon's hyperglycaemic potential by maintaining insulin secretion.
Research Applications
- Dual GLP-1/glucagon receptor signalling research
- Hepatic lipid metabolism and steatosis models
- Thermogenesis and energy expenditure studies
- Metabolic liver disease pathway investigation
- Comparative dual-agonist pharmacology (GIP vs glucagon)